This white paper explores how Touchlight is redefining DNA payload design for next-generation gene editing and non-viral gene therapy. It introduces innovative circular DNA architectures such as mbDNA, sscDNA, hsscDNA, and dscDNA—that enable precise, scalable, and efficient gene insertion across diverse modalities like HDR, HITI, recombination, and transposition. Download this whitepaper to learn how these payloads overcome limitations of traditional templates, reduce cytotoxicity, and unlock new therapeutic possibilities.

In this white paper, you’ll learn:

• Why payload architecture matters: How the structure and composition of DNA templates influence integration efficiency, safety, and therapeutic outcomes.
• Touchlight’s innovations: The unique benefits of custom circular DNA formats (single-stranded, hybrid, and double-stranded) for gene editing and non-viral delivery.
• Future applications: How these technologies enable large gene insertions, improve tolerability by reducing immune activation, and accelerate the development of advanced cell and gene therapies.

As gene therapy accelerates, the demand for scalable viral vector manufacturing has never been greater. Yet traditional plasmid DNA (pDNA) remains a limiting factor, slowed by scalability challenges, bacterial contamination risks, and regulatory constraints.

Discover how Touchlight’s dbDNA, a cell-free alternative to pDNA, is breaking through these bottlenecks.

In this whitepaper, you’ll learn:

• How dbDNA eliminates bacterial sequences and antibiotic resistance genes to streamline regulatory compliance
• Why dbDNA enhances production efficiency for rAAV and rLV vectors
• Real-world data comparing yields, reagent usage, and vector quality against pDNA workflows
• How dbDNA supports large-scale, safe, and scalable vector manufacturing for evolving clinical needs

Whether you’re troubleshooting upstream challenges or planning for commercial-scale production, this whitepaper offers the insights you need to move faster and go further.

Download the whitepaper to explore the data.

In this white paper, authored by Dr Sarah Moore, Head of Gene Therapy Discovery, Touchlight, we discuss major challenges and present approaches to improve overall functional titre, through the optimisation of upstream and downstream processing platforms, as well as strategies for eliminating the requirement for plasmid DNA, including the use of rapid and highly scalable platforms for manufacturing synthetic DNA as a viable alternative to address regulatory hurdles and achieve cost efficiencies.